February 5, 2021 -- Multiparametric MRI-targeted biopsy for clinically significant prostate cancer can yield detection rates similar to systematic transrectal ultrasound-guided (TRUS) biopsy, while potentially enabling over one-third of prostate biopsies to be avoided, according to research published online February 4 in In a multicenter, prospective, and randomized phase III study called PRostate Evaluation for Clinically Important Disease: MRI vs. Standard Evaluation Procedures (PRECISE), a team of researchers from Canada found that providing targeted biopsies after a positive multiparametric MRI scan was noninferior to systematic TRUS biopsies for detecting prostate cancers with an International Society of Urological Pathology grade group (GG) of 2 or higher.